Tempus’ Patient-Derived Organoid (PDO) Screens

Rapidly help evaluate the efficacy of your preclinical drug candidates across a range of therapeutic modalities—including small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), etc.

Currently enrolling panels:

• PanCancer: 60 PDOs across 12 indications (option to enroll in the full panel or a subset of 30 PDOs across 6 indications)
• PanKRAS: 50 PDOs representing ~10 KRAS variants (G12C, G12D, G13D, Q61H, etc.) across the 3 key indications (lung, pancreatic and colorectal)
• PanMSI-H: 30 pan-indication PDOs enriched for MSI-H models
• PanLung: 40 NSCLC PDOs across subtypes (LUAD, LUSC)
• PanCRC: 40 CRC PDOs enriched for pre-treated models

Key insights:

• Viability assessments, including IC₅₀ and EC₅₀ analyses, via luminescence readouts
• Responses to indication- or biomarker-specific standard-of-care (SOC) therapies
• Molecular insights, including Differential Gene Expression (DGE) and Gene Set Enrichment Analysis (GSEA), to identify DNA/RNA drivers of response or resistance

Enrollment is open through June 30th, 2026. Space is limited – complete the form now to secure your spot.